Royalty Report: Drugs, Pain, Therapeutic – Collection: 281807


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Pain
  • Therapeutic
  • Pharmaceuticals
  • Migraine
  • Disease
  • Medical
  • Delivery
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 281807

License Grant
The Licensor of Norway grants to Licensee certain patents and a non-exclusive license to certain know-how to use, sell, offer for sale, have sold and import ONZETRA® XSAIL® (sumatriptan nasal powder).
License Property
ONZETRA® Xsail® is a prescription medication approved for the acute treatment of migraine, with or without aura in adults.  ONZETRA Xsail is used for people who have been told by a healthcare provider that they have migraine headaches.
Field of Use
The field of use is for the acute treatment of migraine in adults.

IPSCIO Record ID: 28656

License Grant
The parties entered an agreement to acquire the U.S rights to Treximet®(sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults.
License Property
Treximet is a tablet containing a combination of sumatriptan and naproxen.

Sumatriptan is a headache medicine. It is believed to work by narrowing the blood vessels around the brain.

IPSCIO Record ID: 214112

License Grant
Canadian Party A signed a license agreement with Party B for the exclusive rights to develop, register, promote, manufacture, use, market, distribute and sell Cambia in Canada.
License Property
Cambia® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (“NSAID”) and currently the only prescription NSAID approved in Canada for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older.

The competitive market for Cambia is to be the triptan class of drugs or 5-HT1 receptor agonists as they are known, which include sumatriptan (Imitrex®), rizatriptan (Maxalt®), zolmitriptan (Zomig®), almotriptan (Axert®), naratriptan (Amerge®), eletriptan (Relpax®) and frovatriptan (Frova®).

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 26033

License Grant
The Licensor grants the Licensee an exclusive license, with the right to sublicense, under Licensor Know-How and Licensed Patents to make, have made, use, sell, offer for sale, and import Compound and Product in the Field in the Territory, which license shall be effective as of the Closing Date. Field means all human health uses.
License Property
Product Lasmiditan, a high-affinity, highly selective serotonin receptor agonist.

The potency and selectivity of lasmiditan make it suited to definitively test  in migraine headache therapy.

Lasmiditan is an oral tablet for the acute treatment of migraine headaches in adults. In the Phase 2b clinical trial of lasmiditan, the primary endpoint.  This was headache relief with statistical significance along with freedom from the associated symptoms of nausea, sensitivity to sound and sensitivity to light. The Licensee is conducting their first Phase 3 clinical trial under a special protocol assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA, with top-line data expected in the third quarter of 2016.

Field of Use
The Licensee is interested in further developing and commercializing LY573144 – Lasmititan.

IPSCIO Record ID: 3006

License Grant
Licensor  retains ex-U.S. rights to develop and market other triptan and NSAID combinations and plans to seek global commercial partners.

Treximet® is a combination of IMITREX (sumatriptan) and prescription-strength naproxen sodium (an NSAID).

License Property
Treximet was approved by the U.S. Food and Drug Administration (FDA) in April 2008 for the acute treatment of migraine attacks, with or without aura, in adults.

IPSCIO Record ID: 203351

License Grant
Licensor grants to Licensee of Denmark an exclusive license under the Licensed Technology to market, sell, offer to sell and distribute for sale Products in the Field within the Territory.

Licensor will grant to Licensee solely for Licensees exclusive sale and distribution for sale within the Field within the Territory a non-exclusive license under the Licensed Technology to use, make, have made, import and export Products in the Field within the Territory.

Licensor grants to Licensee an exclusive license to use the Product Trademarks and Trademarks in connection with the sale and distribution of Products in the Field within the Territory.

License Property
'Product' shall mean an oral formulation of Licensor's MT 100 drug product containing 500mg naproxen sodium and 16mg metoclopramide hydrochloride in tablet form, conforming to the Specifications.

The Licensed Technology means the Know-How, Patents, and any Improvements.  The Initial Product means an oral formulation of Product containing 500mg naproxen sodium and 16mg metoclopramide hydrochloride developed by Licensor as of the Effective Date under the Licensor Marketing Authorization Application for the Initial Indication.  The Initial Indication means the acute treatment of migraine attacks with or without aura.

The Product means any presentation and/or dosage strength of a formulation combining naproxen sodium and metoclopramide hydrochloride for any indication.

MT 100  is being developed as an oral first-line therapy designed to provide effective migraine relief.

Field of Use
The Field is the treatment of human diseases or conditions by means of a prescription pharmaceutical product.

MT 100  is being developed as an oral, first-line treatment for migraine. It is a patented sequential release tablet containing  naproxen sodium , which relieves pain and reduces inflammation, and metoclopramide hydrochloride , which accelerates the absorption of naproxen  and relieves nausea. The results from two head-to-head studies show that  MT 100  provides comparable  efficacy  to  Imitrex (R) 50 mg, the leading prescription product for migraine worldwide, but has less risk of cardiosvascular side effects compared to Imitrex.

IPSCIO Record ID: 7298

License Grant
Israelie Licensee entered into a joint development and commercialization agreement with Canadian Licensor under which Licensor granted us a worldwide, exclusive and perpetual license to use its rights in patents and know-how relating to a triptan formula based on the VersaFilmTM technology and which we call RHB-103. The License includes the right to grant sublicenses.
License Property
The License relate to various patent rights and know-how related to RHB-103. RHB-103 is for the treatment of acute migraine headaches.
Field of Use
The License covers the co-developing, selling, offering for sale and importing the product for all indications, including, but not limited to, acute treatment of migraine attacks with or without an aura and all other therapeutic, diagnostic, and other human /or animal uses.

IPSCIO Record ID: 6811

License Grant
The Company sold all of its assets related to the Intraject needle-free injector technology platform and products, including 12 United States patents along with foreign counterparts, to the Buyer, a privately-held pharmaceutical company. The Buyer is responsible for further development and commercialization efforts of Intraject (now rebranded under the name DosePro). In December 2007, the Buyer submitted a New Drug Application for the migraine drug sumatriptan using the needle-free injector DosePro – Sumavel* DosePro. The NDA was accepted for filing by the FDA in March 2008. The same month, the Buyer entered into a License Agreement to grant exclusive rights in the European Union to Desitin Pharmaceuticals, GmbH to develop and commercialize Sumavel DosePro in the European Union.
License Property
On July 16, 2009, the Buyer announced that it had received approval from the FDA for its NDA for Sumavel DosePro needle-free delivery system. On August 3, 2009, The Buyer and Astellas Pharma US, Inc. announced that they had entered into an exclusive co-promotion Agreement in the U.S. for the Sumavel DosePro needle-free delivery system. Under the announced terms of the Agreement, the companies will collaborate on the promotion and marketing of Sumavel DosePro with Licensee focusing their sales activities primarily on the neurology market while Astellas will focus mostly on primary care physicians. Licensee will have responsibility for manufacturing and distribution of the product. On January 13, 2010, Licensee announced the U.S. commercial launch of its Sumavel DosePro product.
Field of Use
Sumavel DosePro is a pre-filled, single-use disposable, needle-free drug delivery system that subcutaneously delivers 6 mg of sumatriptan in 0.5 ml of sterile liquid.  Sumavel DosePro (sumatriptan injection) is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.

IPSCIO Record ID: 4339

License Grant
The Licensee signed a License Agreement with the Licensor for the exclusive rights to develop, register, promote, manufacture, use, market, distribute and sell Cambia® in Canada.
License Property
Cambia (diclofenac potassium) is a non steroidal anti inflammatory drug (NSAID). This medicine works by reducing substances in the body that cause pain inflammation.
Field of Use
Cambia is used to treat migraine headache attacks, with or without aura, in adults 18 years of age and older.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.